Announcement on Obtaining Drug Registration Certificate for Blonanserin Tablets by its Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Filed with SSE · · 2 pages · Chinese
Zhejiang CONBA Pharmaceutical Co., Ltd. announced that its subsidiary has received a drug registration certificate for Blonanserin Tablets from the National Medical Products Administration. The drug is classified as a second-generation antipsychotic used for treating schizophrenia and has been approved for sale in China. The company plans to actively arrange for the production and market launch of this drug, which is expected to positively impact its performance. Investors are cautioned about potential uncertainties in future sales and revenue due to market and policy factors.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Announcement on Obtaining Drug Registration Certificate for Blonanserin Tablets by its Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Zhejiang CONBA Pharmaceutical Co., Ltd. on 6ix
Follow Zhejiang CONBA Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang CONBA Pharmaceutical